Bio
John joined Ferghana in 2011 to augment our capabilities, assisting in creating and implementing transactions in Australia and the Western US, especially the West Coast, bringing his broad-based experience in the life sciences industry, both from an operating and investment perspective. Most recently John was the founding CEO of Arana Therapeutics, a new generation antibody developer and a Board member of Domantis, Inc. - prior to the acquisition of those companies by Cephalon and GSK, respectively. Immediately prior to running Arana, he was head of the ITI Life Sciences investment fund in the UK. His own investment vehicle, Newstar Ventures Ltd., has funded more than a dozen early stage companies in the past ten years. John has Pharmacy and Doctoral degrees from the University of Nottingham, UK, and he currently serves on the Boards/acts as an advisor to a number of Australian and American companies.
![[current-page:title] logo](/sites/default/files/styles/icon/public/default_images/_no-logo.png?itok=AH4pbDYM){kind=icon}